Medeva walks away from Elan cash bid
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MEDEVA, THE ailing biotechcompany, has walked away from talks with Elan Pharmaceuticals, a Dublin-based company, because of a disagreement over the offer price. Medeva also said yesterday that it was approached in July by Shire Pharmaceuticals, its rival, but had not entered talks with them.
Medeva revealed on 8 September that it was in talks with an unnamed bidder and has since refrained from naming the company in question. Dr Bill Bogie, chief executive, said the board had had no hesitation in rejecting the subsequent cash offer. He declined to indicate the value of the bid.
However, sources confirmed the bid was 158p per share and that it came from Elan. They added that the Dublin company might take the bid hostile. Elan declined to comment.
"I'm sure we could have negotiated a few pennies here and there, but the offer was so far below the valuations put on the company by our advisers there was no point," Dr Bogie said.
Dr Bogie said Shire had approached the group in July in what was nothing more than a "dalliance", which had not resulted in formal talks. Previously, the group had declined to comment on rumours that talks between the two had collapsed. Dr Bogie said talks with Shire remained a possibility. He also rejected suggestions that Medeva directors were facing mounting shareholder criticism.
Medeva shares fell 22 per cent, to 132p, valuing the company at pounds 451m. The shares were at 122p on the day before talks were announced.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments